A Vehicle-Controlled, Double-Blind, Randomized Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Mild to Moderate Rosacea
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2019
At a glance
- Drugs B 244 (Primary)
- Indications Rosacea
- Focus Adverse reactions
- Sponsors AOBiome
- 08 Jan 2019 Planned End Date changed from 1 Jan 2019 to 1 Jun 2019.
- 08 Jan 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Mar 2019.
- 07 Dec 2018 Status changed from recruiting to active, no longer recruiting.